UPDATE ON BRODALUMAB DEVELOPMENT PROGRAMME


AstraZeneca Provides Update on Brodalumab Development Programme

Amgen has
announced (http://www.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=20
5 
2862) the termination of its co-development and commercialisation agreement with
AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in
development for patients with moderate-to-severe plaque psoriasis, psoriatic
arthritis, and axial spondyloarthritis. The announcement follows Amgen's
decision to concentrate on other portfolio priorities after observing suicidal
ideation and behaviour events in the brodalumab programme which may result in
restrictive labelling.

AstraZeneca will confirm its decision on the future development of brodalumab as
soon as possible, based on further review of the data.

Briggs Morrison, Executive Vice President, Global Medicines Development and
Chief Medical Officer at AstraZeneca, said: "Data from the three AMAGINE Phase
III pivotal studies highlighted that brodalumab has an effective mechanism of
action that delivers clinical benefit. We will fully evaluate the data and
assess all options before we make our independent decision about the future of
this potential medicine."

About Brodalumab (AMG 827)

Brodalumab is a novel human monoclonal antibody that binds to the interleukin-17
(IL-17) receptor and inhibits inflammatory signaling by blocking the binding of
several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating
the receptor, brodalumab prevents the body from receiving signals that may lead
to inflammation. The IL-17 pathway plays a central role in inducing and
promoting inflammatory disease processes.

About the Amgen and AstraZeneca Collaboration

In April 2012, Amgen and AstraZeneca formed a collaboration to jointly develop
and commercialise five monoclonal antibodies from Amgen's clinical inflammation
portfolio.  With oversight from joint governing bodies, Amgen leads clinical
development and commercialisation for brodalumab and AMG 557/MEDI5872 (Phase Ib
for autoimmune disease, such as systemic lupus erythematosus).  AstraZeneca,
through its biologics arm MedImmune, leads clinical development and
commercialisation for MEDI7183/AMG181 (Phase II for ulcerative colitis and
Crohn's disease), MEDI2070/AMG139 (Phase II for Crohn's disease) and
MEDI9929/AMG157 (Phase II for asthma).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)
Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)
Jacob Lund                                  +46 8 553 260 20 (Sweden)
Michele Meixell                            + 1 302 885 6351 (US)

Investor Enquiries

Thomas                       +44 20 7604 8199     mob: +44 7818 524185
Kudsk
Larsen
Eugenia    Respiratory,      +44 20 7604 8233     mob: +44 7884 735627
Litz       Inflammation and
           Autoimmunity
Nick       Cardiovascular    +44 17 6326 3994     mob: +44 7717 618834
Stone      and Metabolic
           Disease
Karl Hård  Oncology          +44 20 7604 8123     mob: +44 7789 654364
Craig      Infection,        +44 20 7604 8591     mob: +44 7881 615764
Marks      Neuroscience
           and
           Gastrointestinal
           Disease
Christer                     +44 20 7604 8126     mob: +44 7827 836825
Gruvris

25 May 2015